Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for Setmelanotide – What’s Changed

• In June 2026, Rhythm Pharmaceuticals reported preliminary six-month Phase 2 data for setmelanotide in Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and anxiety-related behaviors, with safety consistent with prior experience and 17 of 18 patients remaining on therapy.
• The breadth of clinically relevant benefits across weight, hunger, and behavioral measures in a difficult-to-treat PWS population could meaningfully influence how investors think about setmelanotide’s longer-term potential beyond its current rare obesity indications.
• We’ll now examine how these early, multi-dimensional improvements in PWS patients might reshape Rhythm’s existing investment narrative around setmelanotide.

We’ve uncovered the 7 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.

Rhythm Pharmaceuticals Investment Narrative Recap

To own Rhythm Pharmaceuticals, you need to believe setmelanotide can sustain and broaden its role in rare obesity, while the company narrows losses and reduces reliance on a single asset. The new Prader Willi data supports scientific momentum, but the key near term catalyst remains execution on recently expanded hypothalamic obesity labels, while the biggest risk is still ongoing operating losses and potential dilution. Overall, the PWS readout modestly strengthens, rather than transforms, the story.

Among recent announcements, the US FDA and European Commission approvals of setmelanotide for acquired hypothalamic obesity stand out as most connected to this PWS update, as both speak to Rhythm’s effort to extend the MC4R agonist into additional high unmet need populations. Together with the PWS Phase 2 signals, these developments frame how future revenue could depend on successfully converting emerging clinical data into reimbursed, sustainable commercial use across multiple tightly defined indications.

Yet despite this encouraging progress, investors should still be aware that Rhythm remains unprofitable and may ultimately need to raise additional capital…

Read the full narrative on Rhythm Pharmaceuticals (it’s free!)

Rhythm Pharmaceuticals’ narrative projects $971.3 million revenue and $263.4 million earnings by 2029.

Uncover how Rhythm Pharmaceuticals’ forecasts yield a $139.47 fair value, a 44% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range, from about US$139 to nearly US$473 per share, showing just how far apart individual views can be. When you contrast that dispersion with Rhythm’s continued operating losses and dependence on setmelanotide, it underlines why many readers may want to compare several opinions before forming expectations about the company’s future performance.

Explore 2 other fair value estimates on Rhythm Pharmaceuticals – why the stock might be worth just $139.47!

Reach Your Own Conclusion

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

• A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Rhythm Pharmaceuticals’ overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com